This Forum explored the challenges and complexities of drug trials, and how they impact disease treatment and prevention - particularly for conditions that currently have little or no therapeutic options. As a case study, the panel discussed Alzheimer’s and several drugs in development for that disease, but also addressed broader concerns related to the pharmaceutical testing pipeline for unmet medical needs as a whole. This event was presented in partnership with HHMI Tangled Bank Studios, in collaboration with STAT, and in association with NOVA.
The latest in a recent spate of books and movies that have brought Alzheimer’s to a broader public, a new NOVA documentary ow explores what it takes to go from basic research to treatment trials. In her film “Can Alzheimer’s Be Stopped?” three-time Emmy award and AAAS Science Journalism award-winning producer Sarah Holt tells the story of Alzheimer’s research. Her film conveys the challenges and staggering cost of research and personalizes the emotional toll Alzheimer’s takes on patients, caregivers, and even researchers.
On a recent flight from San Francisco back to Boston, I found myself seated between my 28-year-old daughter Colleen and the emergency hatch. When the attendant had asked if I could perform the duties, I shrugged and simply said I was afraid of heights. I forgot about the confusion part. I forgot why doctors don’t let me travel alone any more. Alzheimer’s will do that.
t’s easy to think that the mysteries of Alzheimer’s disease will be revealed in the high-tech hallways of US medical centers and research institutes. But new discoveries are coming from far-off places like Medellín, Colombia, which may be ground zero for finding the genetic basis of this dreaded neurodegenerative disease that strips people of memories and destroys personalities.
Thousands of gene candidates in the human genome have the potential to play a role in the onset and progression of Alzheimer’s disease. But you are just one scientist. How can you even start such an enormous task? This quest - one scientist analyzing thousands of gene candidates - can seem overwhelming.
Harvard Medical School researchers at Boston Children’s Hospital explain in a new paper how brain connections, or synapses, are lost early in Alzheimer’s disease. They also show that the process starts before telltale plaques accumulate in the brain.
Their work, published online March 31 in Science, suggests new therapeutic targets to preserve cognitive function early in Alzheimer’s disease.
More than 99% of clinical trials for Alzheimer’s drugs have failed, leading many to wonder whether pharmaceutical companies have gone after the wrong targets. Now, research in mice points to a potential new target: a developmental process gone awry, which causes some immune cells to feast on the connections between neurons.
“It is beautiful new work,” which “brings into light what’s happening in the early stage of the disease,” says Jonathan Kipnis, a neuroscientist at the University of Virginia School of Medicine in Charlottesville.
Even the simplest networks of neurons in the brain are composed of millions of connections. Examining these vast networks is critical to understanding how the brain works, and now, an international team of researchers, led by Wei-Chung Allen Lee, instructor in neurobiology at Harvard Medical School, R. Clay Reid of the Allen Institute for Brain Science in Seattle and Vincent Bonin of Neuro-Electronics Research Flanders (NERF), has published the largest network to date of connections between neurons in the visual cortex.
In the early stages of Alzheimer’s disease, patients are often unable to remember recent experiences. However, a new study from MIT suggests that those memories are still stored in the brain — they just can’t be easily accessed.
The MIT neuroscientists report in Nature that mice in the early stages of Alzheimer’s can form new memories just as well as normal mice but cannot recall them a few days later.
The National Institute on Aging (NIA) and the National Institute of Neurological Disorders and Stroke (NINDS), both part of the National Institutes of Health (NIH), have launched the Molecular Mechanisms of the Vascular Etiology of Alzheimer’s Disease (M²OVE-AD) Consortium to better understand how the body’s vascular system, its network of large and small blood vessels, contributes to Alzheimer’s disease.